Satsuma Pharmaceuticals Stock Earnings Per Share
| STSADelisted Stock | USD 1.10 0.01 0.90% |
Satsuma Pharmaceuticals fundamentals help investors to digest information that contributes to Satsuma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Satsuma Stock. The fundamental analysis module provides a way to measure Satsuma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Satsuma Pharmaceuticals stock.
Satsuma |
Satsuma Pharmaceuticals Company Earnings Per Share Analysis
Satsuma Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Satsuma Pharmaceuticals Earnings Per Share | (1.99) X |
Most of Satsuma Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Satsuma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Satsuma Pharmaceuticals has an Earnings Per Share of -1.99 times. This is 123.78% lower than that of the Pharmaceuticals sector and 58.46% lower than that of the Health Care industry. The earnings per share for all United States stocks is 163.78% higher than that of the company.
Satsuma Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Satsuma Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Satsuma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics of similar companies.Satsuma Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Satsuma Fundamentals
| Return On Equity | -1.04 | |||
| Return On Asset | -0.5 | |||
| Current Valuation | (35.53 M) | |||
| Shares Outstanding | 33.15 M | |||
| Shares Owned By Insiders | 10.43 % | |||
| Shares Owned By Institutions | 57.90 % | |||
| Number Of Shares Shorted | 130.12 K | |||
| Price To Earning | 22.12 X | |||
| Price To Book | 0.42 X | |||
| EBITDA | (58.31 M) | |||
| Net Income | (70.06 M) | |||
| Cash And Equivalents | 68.06 M | |||
| Cash Per Share | 2.15 X | |||
| Total Debt | 205 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 9.18 X | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (51.52 M) | |||
| Short Ratio | 0.05 X | |||
| Earnings Per Share | (1.99) X | |||
| Price To Earnings To Growth | 4.50 X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 25 | |||
| Beta | 0.1 | |||
| Market Capitalization | 36.8 M | |||
| Total Asset | 54.94 M | |||
| Retained Earnings | (211.79 M) | |||
| Working Capital | 46.69 M | |||
| Z Score | 99.83 | |||
| Net Asset | 54.94 M |
About Satsuma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Satsuma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satsuma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satsuma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |